BACKGROUND: A phase 2 trial was conducted to assess in young infants thesafety, tolerability, infectivity, and immunogenicity of multiple doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3). METHODS:One hundred ninety-two healthy 2-month-old infants were randomized 1 : 1 : 1 to receive 1x10(5) median tissue culture infective dose (TCID(50)) bPIV3 vaccine, 1x10(6) TCID(50) bPIV3 vaccine, or placebo at 2, 4, 6, and 12-15 months of age. Safety information was collected by use of diary sheets and telephone interviews. Nasal wash and serum specimens were collected for assessment of infectivity and immunogenicity. RESULTS: The safety profiles of both dosages of bPIV3 were similar to that of placebo, with the exception of fever with temperature of >/=38.1 degrees C after dose 2 only, occurring in 34% of the 1x10(5) TCID(50) group, 35% of the 1x10(6) TCID(50) group, and 12% of the placebo group (P<.01). No vaccine-related serious adverse events were reported. The cumulative vaccine infectivity (isolation of bPIV3 and/or bPIV3 seroconversion) after dose 3 was similar in the 2 vaccine groups (87% in the 1x10(5) TCID(50) group and 77% in the 1x10(6) TCID(50) group) (P=.46). Seroconversion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment for decrease in maternal antibody titers, were 67% in the 1x10(5) TCID(50) group, 57% in the 1x10(6) TCID(50) group, and 12% in the placebo group (P<.01). Isolation of bPIV3 was common after dose 1, dose 2, or dose 3, but only 1 of 51 participants in the vaccine groups had bPIV3 isolated after dose 4. CONCLUSIONS: Multiple doses of bPIV3 vaccine were well tolerated and immunogenic in young infants.
RCT Entities:
BACKGROUND: A phase 2 trial was conducted to assess in young infants the safety, tolerability, infectivity, and immunogenicity of multiple doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3). METHODS: One hundred ninety-two healthy 2-month-old infants were randomized 1 : 1 : 1 to receive 1x10(5) median tissue culture infective dose (TCID(50)) bPIV3 vaccine, 1x10(6) TCID(50) bPIV3 vaccine, or placebo at 2, 4, 6, and 12-15 months of age. Safety information was collected by use of diary sheets and telephone interviews. Nasal wash and serum specimens were collected for assessment of infectivity and immunogenicity. RESULTS: The safety profiles of both dosages of bPIV3 were similar to that of placebo, with the exception of fever with temperature of >/=38.1 degrees C after dose 2 only, occurring in 34% of the 1x10(5) TCID(50) group, 35% of the 1x10(6) TCID(50) group, and 12% of the placebo group (P<.01). No vaccine-related serious adverse events were reported. The cumulative vaccine infectivity (isolation of bPIV3 and/or bPIV3 seroconversion) after dose 3 was similar in the 2 vaccine groups (87% in the 1x10(5) TCID(50) group and 77% in the 1x10(6) TCID(50) group) (P=.46). Seroconversion rates after dose 3, assessed by means of hemagglutination inhibition assay, after adjustment for decrease in maternal antibody titers, were 67% in the 1x10(5) TCID(50) group, 57% in the 1x10(6) TCID(50) group, and 12% in the placebo group (P<.01). Isolation of bPIV3 was common after dose 1, dose 2, or dose 3, but only 1 of 51 participants in the vaccine groups had bPIV3 isolated after dose 4. CONCLUSIONS: Multiple doses of bPIV3 vaccine were well tolerated and immunogenic in young infants.
Authors: Linda G Brock; Xiang Liu; Bo Liang; Matthias Lingemann; Xueqiao Liu; Richard Herbert; Ashley D Hackenberg; Ursula J Buchholz; Peter L Collins; Shirin Munir Journal: J Virol Date: 2018-08-16 Impact factor: 5.103
Authors: Kawsar R Talaat; Ruth A Karron; Bhagvanji Thumar; Bridget A McMahon; Alexander C Schmidt; Peter L Collins; Ursula J Buchholz Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins Journal: Expert Rev Respir Med Date: 2011-08 Impact factor: 3.772
Authors: Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata Journal: Cochrane Database Syst Rev Date: 2017-05-18
Authors: Emmalene J Bartlett; Ann-Marie Cruz; Janice Esker; Adam Castaño; Henrick Schomacker; Sonja R Surman; Margaret Hennessey; Jim Boonyaratanakornkit; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt Journal: J Virol Date: 2008-07-09 Impact factor: 5.103
Authors: Emmalene J Bartlett; Ann-Marie Cruz; Jim Boonyaratanakornkit; Janice Esker; Adam Castaño; Mario H Skiadopoulos; Peter L Collins; Brian R Murphy; Alexander C Schmidt Journal: Vaccine Date: 2009-10-24 Impact factor: 3.641
Authors: Shu Ting Luo; Pai Shan Chiang; An Shine Chao; Guan Yuan Liou; Reyin Lin; Tzou Yien Lin; Min Shi Lee Journal: Emerg Infect Dis Date: 2009-04 Impact factor: 6.883